Cost-effective Treatment: A Closer Look at SGLT2 Inhibitors

By Staff Writer

March 26, 2024

Introduction:

The healthcare industry is continually evolving, with medical advancements reshaping the way we approach disease management. One area of significant progress is in the treatment of Type 2 Diabetes (T2D), where Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors are emerging as a potent weapon, particularly to manage other comorbidities such as cardiac failure, kidney function and anaemia. Besides their glucose-lowering and kidney-protective effects, SGLT2s have the potential to increase haemoglobin levels in T2D patients. This article we have a closer look at the efficacy and cost-effectiveness of SGLT2 inhibitors, providing insight into their potential role in the future for various conditions.

SGLT2 Inhibitors and Anaemia Prevention:

SGLT2 inhibitors have demonstrated effectiveness in the management of T2D, congestive heart failure (CCF), and chronic kidney disease (CKD). These inhibitors work by reducing the reabsorption of glucose in the kidneys, thereby lowering blood glucose levels. Anaemia commonly affects patients with T2D and it is associated with higher mortality rates. This condition also lowers the quality of life. Currently, healthcare guidelines do not include precise recommendations for adjuvant therapy aimed at preventing the onset of anaemia.

Recent studies suggest a significant role for SGLT2 inhibitors in mitigating risks of CKD and anaemia in patients with T2D. These inhibitors are linked to a 38% risk reduction in kidney outcomes. They also correlate with increased haemoglobin levels in these patients. 

The Cost-Effectiveness of SGLT2 Inhibitors in Heart Failure

SGLT2 inhibitors have shown promising results in the management of heart failure with preserved ejection fraction (HFpEF), a condition affecting approximately 3 million US adults. Recent clinical trials have demonstrated that SGLT2 inhibitors significantly reduced the risk of heart failure hospitalisation or cardiovascular death compared to a placebo.

However, the cost-effectiveness of these drugs is a crucial consideration. Currently, the average wholesale price for a one-year supply of SGLT2 inhibitors is approximately $8000, while the Federal Supply Schedule cost is about $4500. This high cost could significantly increase pharmaceutical spending, potentially hindering the widespread uptake of these effective cardiovascular therapies.

The Economic Value of SGLT2 Inhibitors

An economic evaluation using a simulation model of US adults with HFpEF projected that adding an SGLT2 inhibitor to standard care would increase quality-adjusted survival by 0.19 years (equivalent to approximately 69 additional days of perfect health). However, it would also increase lifetime costs by $26,300. This results in an incremental cost-effectiveness ratio (ICER) of $141,200 per quality-adjusted life year (QALY) gained, which is considered an intermediate-value strategy.

However, the economic value is sensitive to the association with cardiovascular mortality. A small increase in cardiovascular mortality could make SGLT2 inhibitors a low-value strategy. If the annual cost of SGLT2 inhibitors is lowered to $1431, a 68% reduction from the current Veterans Affairs price and a 78% reduction in wholesale acquisition cost, SGLT2 inhibitors could be considered high to intermediate value.

Conclusion

While SGLT2 inhibitors offer significant benefits in managing T2D, CKD, anaemia, and CCF, their high cost can be a barrier to their widespread use. However, the potential availability of generic versions of these drugs could significantly improve their cost-effectiveness. The healthcare industry constantly aims to offer superior, more cost-efficient solutions for patients. Consequently, we anticipate an increased role for SGLT2 inhibitors in managing these conditions. 

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.